Amino-terminal pro-B-type brain natriuretic peptide: Screening for cardiovascular disease in the setting of alcoholism

Alcohol and Alcoholism

Volumn 46, Issue 3, 2011, Pages 247-252

  Höfer, Peter ^a   Syeda, Bonni ^a   Bergler Klein, Jutta ^a   Friedrich, Fabian ^a   Lesch, Otto Michael ^a   Vyssoki, Benjamin ^a   Binder, Thomas ^a   Walter, Henriette ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; GENDER; HEART; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHIATRY; SCREENING; SEX DIFFERENCE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; ALCOHOLISM; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COMORBIDITY; ECHOCARDIOGRAPHY; ETHANOL; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; STROKE VOLUME;

EID: 79955391459     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agr027     Document Type: Article

References (39)

1. Babor TF, De Hofmann MI, Boca FK et al. (1992) Types of alcoholics: I. Evidence for an empirically derived typology based on indicator of vulnerability and severity. Arch Gen Psychiatry 49:599-608.
2. Bai M, Yang J, Li Y. (2009) Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation. Clin Cardiol 32:E1-5.
3. Bergler-Klein J, Klaar U, Heger M et al. (2004) Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109:2302-8.
4. Cloninger CR, Bohman M, Sigvardsson S. (1981) Inheritance alcohol abuse: cross fostering analysis of adopted men. Arch Gen Psychiatry 38:861-8.
5. Conen D, Tedrow UB, Cook NR et al. (2008) Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 300:2489-96.
6. Costanzo S, Di Castelnuovo A, Donati MB et al. (2010) Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease. Circulation 121:1951-9.
7. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47:345-53.
8. Dahmen N, Völp M, Singer P et al. (2005) Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism. Psychiatr Genet 15:13-6.
9. Daniels LB, Maisel AS. (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357-68.
10. Dawes MA, Johnson BA, Ait-Daoud N et al. (2005) A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 30:1077-85.
11. de Lemos JA, Morrow DA, Bentley JH et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014-21.
12. de Lemos JA, McGuire DK, Drazner MH. (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316-22.
13. Di Castelnuovo A, Costanzo S, Bagnardi V et al. (2006) Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 166:2437-45.
14. Djoussé L, Levy D, Benjamin EJ et al. (2004) Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 93:710-3.
15. Galasko GI, Lahiri A, Barnes SC et al. (2005) What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 26:2269-76.
16. Janszky I, Ljung R, Ahnve S et al. (2008) Alcohol and long-term prognosis after a first acute myocardial infarction: the SHEEP study. Eur Heart J 29:45-53.
17. Johnson BA. (2010) Medication treatment of different types of alcoholism. Am J Psychiatry 167:630-9. Review.
18. Kim SD, Beck J, Bieniarz T et al. (2001) A rodent model of alcoholic heart muscle disease and its evaluation by echocardiography. Alcohol Clin Exp Res 25:457-63.
19. Kim SD, Bieniarz T, Esser KA et al. (2003) Cardiac structure and function after short-term ethanol consumption in rats. Alcohol 29:21-9.
20. Leggio L, Kenna GA, Fenton M et al. (2009) Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol Rev 19:115-29. Review.
21. Lesch OM, Dietzel M, Musalek M et al. (1988) The course of alcoholism. Long-term prognosis in different types. Forensic Sci Int 36:121-38.
22. Lesch OM, Walter H, Wetschka C et al. (2011) Alcohol and Tobacco. Medical and Sociological Aspects of Use, Abuse and Addiction. 1st edn, Vienna: Springer.
23. Maeda K, Tsutamoto T, Wada A et al. (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587-93.
24. Markham DW, de Lemos JA. (2005) Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humours. Eur Heart J 26:2220-1.
25. Moe GW. (2006) B-type natriuretic peptide in heart failure. Curr Opin Cardiol 21:208-14.
26. Mukamal KJ. (2003) Alcohol use and prognosis in patients with coronary heart disease. Prev Cardiol 6:93-8.
27. Mukamal KJ, Psaty BM, Rautaharju PM et al. (2007) Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. Am Heart J 153:260-6.
28. Nagaya N, Nishikimi T, Goto Y et al. (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135:21-8.
29. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE et al. (2002) Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol 37:67-73.
30. Otterstad JE, Froeland G, St John Sutton M et al. (1997) Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 18:507-13.
31. Padillo J, Rioja P, Muñoz-Villanueva MC et al. (2010) BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 22:1331-6.
32. Radvan M, Svoboda P, Radvanová J et al. (2009) Brain natriuretic peptide in decompensation of liver cirrhosis in non-cardiac patients. Hepatogastroenterology 56:181-5.
33. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976-82.
34. Richards AM, Doughty R, Nicholls MG et al. (1999) Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99:786-92.
35. Sesso HD, Cook NR, Buring JE et al. (2008) Alcohol consumption and the risk of hypertension in women and men. Hypertension 51:1080-7.
36. Sobell LC, Sobell MB. (1992) Timeline follow-back: a technique for assessing self-reported ethanol consumption. In Allen J, Litten RZ (eds). Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Human Press, 41-72.
37. Stanek B, Frey B, Hülsmann M et al. (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38:436-42.
38. Wang TJ, Larson MG, Levy D et al. (2002) Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90:254-8.
39. Weiser P, Becker T, Losert C et al. (2009) European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods. BMC Public Health 9:315.